Immunovant(IMVT)
DURHAM, NC
BiotechnologyFocus: Monoclonal Antibody
Immunovant is a life sciences company focused on Monoclonal Antibody.
NeurologyImmunologyEndocrinology
Funding Stage
PUBLIC
Open Jobs
4
Pipeline & Clinical Trials
RVT-1401
Graves' OphthalmopathyClinical Trials (1)
NCT03922321Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)
Phase 2RVT-1401 680 mg/weekly
Warm Autoimmune Hemolytic AnemiaClinical Trials (1)
NCT04253236To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).
Phase 2IMVT-1402
Rheumatoid ArthritisClinical Trials (1)
NCT06754462A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
Phase 2Phase 2
Clinical Trials (1)
NCT06980805A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
Phase 2IMVT-1402
Graves' DiseaseClinical Trials (1)
NCT07018323A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Phase 2RVT-1401
Myasthenia GravisClinical Trials (1)
NCT03863080A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
Phase 2IMVT-1402
Graves' DiseaseClinical Trials (1)
NCT06727604A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Phase 2Phase 2
Clinical Trials (1)
NCT07188844An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 2IMVT-1402
Graves' DiseaseClinical Trials (1)
NCT07286006A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
Phase 2IMVT-1402
Primary Sjögren's SyndromeClinical Trials (1)
NCT06979531Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
Phase 2Phase 2
Clinical Trials (1)
NCT07032662IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 2IMVT-1401
Graves DiseaseClinical Trials (1)
NCT05907668A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
Phase 2Batoclimab 680 milligrams
Chronic Inflammatory Demyelinating PolyneuropathyClinical Trials (1)
NCT05581199To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
Phase 2RVT-1401
Graves' Ophthalmopathy (GO)Clinical Trials (1)
NCT03938545ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )
Phase 2Batoclimab
Thyroid Eye DiseaseClinical Trials (1)
NCT05517421Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Phase 3Observational cohort study
Thyroid Eye DiseaseClinical Trials (1)
NCT05517447Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
Phase 3Batoclimab 680 mg SC weekly
Generalized Myasthenia GravisClinical Trials (1)
NCT05403541Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
Phase 3IMVT-1402
Generalized Myasthenia GravisClinical Trials (1)
NCT07039916Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Phase 3Batoclimab
Thyroid Eye DiseaseClinical Trials (1)
NCT05524571Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Phase 3Open Jobs (4)
Interview Prep Quick Facts
Portfolio: 19 clinical trials
SEC Filings: 2 available
Open Roles: 4 active jobs
Hiring Trend
Stable
4
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles